research use only

TBB Casein Kinase inhibitor

Cat.No.S5265

TBB (4,5,6,7-tetrabromobenzotriazole) is a selective cell-permeable CK2 inhibitor with IC50 values of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively.
TBB Casein Kinase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 434.71

Quality Control

Batch: S526501 DMSO]86 mg/mL]false]]]false]]]false Purity: 99.68%
99.68

Chemical Information, Storage & Stability

Molecular Weight 434.71 Formula

C6HBr4N3

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 17374-26-4 -- Storage of Stock Solutions

Synonyms 4,5,6,7-tetrabromobenzotriazole Smiles C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br

Solubility

In vitro
Batch:

DMSO : 86 mg/mL (197.83 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
CK2 [1]
(Cell-free assay)
0.4 μM(Ki)
CK1 [1]
(Cel-free assay)
47 μM(Ki)
In vitro
In the presence of 10 μM TBB (and 100 μM ATP) only CK2 was drastically inhibited (s85%) whereas three kinases (phosphorylase kinase, glycogen synthase kinase 3L and cyclin-dependent kinase 2/cyclin A) underwent moderate inhibition, with IC50 values one-two orders of magnitude higher than CK2 (IC50 = 0.9 μM). This compound discriminates between CK2 and CK1, being much more e¡ective with the former[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02812290 Recruiting
Lung Transplant Rejection
University of Alberta
May 2016 --
NCT02235779 Unknown status
Interstitial Lung Disease
Laval University
August 2014 Not Applicable
NCT00888212 Completed
Sarcoidosis
University Hospital Ghent
June 2008 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.